<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Overview of the research work published using CQ or HCQ and treatment regimen employed</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left"/>
    <th align="left">Doses of CQ/HCQ tested</th>
    <th align="left">Regimen</th>
    <th align="left">Reference</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">1</td>
    <td align="left">Prophylactic study: CQ (0.1–10 μM) for 20–24 h before infection, CQ (0.1–100 μM) immediate after infection for therapeutic study in primate Vero E6 cells</td>
    <td align="left">Prophylactic and Therapeutic</td>
    <td align="left">Chloroquine is a potent inhibitor of SARS coronavirus infection and spread (Vincent et al. 
     <xref ref-type="bibr" rid="CR53">2005</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">2</td>
    <td align="left">HCQ (400 mg), twice daily, followed by a maintenance dose of 200 mg given twice daily for 4 days to Vero E6 cells</td>
    <td align="left">Therapeutic</td>
    <td align="left">In vitro antiviral activity and projection of optimized dosing design of HCQ for the treatment of SARS-CoV-2 (Yao et al. 
     <xref ref-type="bibr" rid="CR62">2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">3</td>
    <td align="left">CQ (500 mg) twice daily for 10 days</td>
    <td align="left">Therapeutic</td>
    <td align="left">Expert consensus from Department of Science and Technology and Health Commission of Guangdong province, China (Jie et al. 
     <xref ref-type="bibr" rid="CR25">2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">4</td>
    <td align="left">CQ (500 mg) twice daily for 5 days plus Darunavir (800 mg)/Cobicistat (150 mg) once daily for 2 weeks</td>
    <td align="left">Therapeutic</td>
    <td align="left">Centre for Disease Control and Prevention, Atlanta, MICC Version 1 (CDC MICC 
     <xref ref-type="bibr" rid="CR9">2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">5</td>
    <td align="left">CQ (600 mg) of base followed by 300 mg after 12 h on day 1, then 300 mg, twice/day</td>
    <td align="left">Therapeutic</td>
    <td align="left">The Dutch Center of Disease Control (Ministry of Health, welfare and sport. 
     <xref ref-type="bibr" rid="CR35">2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">6</td>
    <td align="left">HCQ (400 mg) twice daily then 12 h later start 400 mg once daily for 5–10 days</td>
    <td align="left">Therapeutic</td>
    <td align="left">Mount Sinai Health System, Canada. (Dugdale 
     <xref ref-type="bibr" rid="CR18">2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">7</td>
    <td align="left">HCQ (400 mg) twice daily followed by 200 mg twice daily for 4 days</td>
    <td align="left">Therapeutic</td>
    <td align="left">Surviving Sepsis Campaign Rapid Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (Alhazzani et al. 
     <xref ref-type="bibr" rid="CR2">2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">8</td>
    <td align="left">CQ (500 mg) twice per day for no more than 10 days</td>
    <td align="left">Therapeutic</td>
    <td align="left">Caution and clarity required in the use of chloroquine for COVID-19 (He et al. 
     <xref ref-type="bibr" rid="CR23">2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">9</td>
    <td align="left">CQ (600 mg) on day 1, then 300 mg twice daily for 5 days or Remdesivir for 100 mg once daily for 2 to 10 days</td>
    <td align="left">Therapeutic</td>
    <td align="left">Interm Clinical Guidance For Adults With Suspected or Confirmed COVID-19 in Belgium (Belgium Task Force 
     <xref ref-type="bibr" rid="CR4">2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">10</td>
    <td align="left">HCQ associated with azithromycin (500 mg at day 1 followed by 250 mg once daily the next 4 days)</td>
    <td align="left">Therapeutic</td>
    <td align="left">HCQ and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial (Gautret et al. 
     <xref ref-type="bibr" rid="CR21">2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">11</td>
    <td align="left">CQ (300 mg) once weekly alone or in combination with proguanil 200 mg daily</td>
    <td align="left">Prophylactic</td>
    <td align="left">Compliance and tolerability of mefloquine and chloroquine plus proguanil for long-term malaria chemoprophylaxis in groups at particular risk (the military) (Peragallo et al. 
     <xref ref-type="bibr" rid="CR39">1999</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">12</td>
    <td align="left">CQ (100 mg) daily or HCQ (300 mg) weekly</td>
    <td align="left">Prophylactic</td>
    <td align="left">Protecting Chinese healthcare workers while combating the 2019 novel coronavirus (Zhou et al. 
     <xref ref-type="bibr" rid="CR65">2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">13</td>
    <td align="left">CQ (500 mg) once weekly</td>
    <td align="left">Prophylactic</td>
    <td align="left">Landscape analysis of therapeutics as 21st March 2020 (WHO 
     <xref ref-type="bibr" rid="CR59">2020a</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">14</td>
    <td align="left">CQ (500 mg) twice daily for 10 days</td>
    <td align="left">Prophylactic</td>
    <td align="left">Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia (Jie et al. 
     <xref ref-type="bibr" rid="CR25">2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">15</td>
    <td align="left">HCQ (400 mg) twice daily, followed by once weekly</td>
    <td align="left">Prophylactic</td>
    <td align="left">Indian Council of Medical Research. Advisory on the use of hydroxy-chloroquine as prophylaxis for SARS-CoV-2 infection (ICMR 
     <xref ref-type="bibr" rid="CR24">2020</xref>, Kalantri et al. 
     <xref ref-type="bibr" rid="CR26">2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">16</td>
    <td align="left">CQ (500 mg) or HCQ (1200 mg)</td>
    <td align="left">Prophylactic</td>
    <td align="left">Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases (Shah et al. 
     <xref ref-type="bibr" rid="CR47">2020</xref>)
    </td>
   </tr>
   <tr>
    <td align="left">17</td>
    <td align="left">HCQ (6 mg/kg/day 1 (loading dose) followed by 5 mg/kg/day), with a maximum limit of 600 mg/day</td>
    <td align="left">Post exposure</td>
    <td align="left">Coalition: advocacy for prospective clinical trials to test the post exposure potential of hydroxychloroquine against COVID-19 (Picot 
     <xref ref-type="bibr" rid="CR40">2020</xref>).
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
